Key result
Advanced AL cardiac amyloidosis with bilateral atrial appendage thrombosis proves fatal despite guideline-directed therapy.
Case Report (n=1)
No
This case highlights the severe thrombotic risk and rapid clinical deterioration associated with advanced AL cardiac amyloidosis, where bilateral atrial appendage thrombosis can occur even without atrial fibrillation.
Fatal deterioration after medication discontinuation in advanced AL amyloidosis warrants sustained adherence; leaves open anticoagulation strategies absent atrial fibrillation.
Light chain cardiac amyloidosis (AL-CA) is a severe and progressively infiltrative disease caused by the deposition of misfolded monoclonal immunoglobulin light chains in the myocardial extracellular space. It is associated with poor prognosis and typically presents as diastolic heart failure, arrhythmias, and atrial appendage thrombosis. We report a case of light chain cardiac amyloidosis with bilateral atrial appendage thrombosis. The patient died from refractory heart failure four months after diagnosis.
No takes yet. Share an insight, caveat, or question.
Jia et al. (2026) conducted a case report in Light chain cardiac amyloidosis (n=1). Rivaroxaban and heart failure medical therapy was evaluated on Clinical outcome. A 70-year-old woman with advanced light chain cardiac amyloidosis and bilateral atrial appendage thrombosis died from refractory heart failure four months after diagnosis despite supportive care.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: